Skip to main content
Premium Trial:

Request an Annual Quote

Sticking to Strategy, Qiagen Licenses Reagent Tech to Kreatech Bio; Plots More OEM Deals


Qiagen last week took another step towards making its technology broadly accessible to microarray users by announcing a non-exclusive licensing agreement with Kreatech Biotechnology.

Under the terms of agreement, Kreatech now has a license to sell Qiagen's Repli-g whole genome amplification technology with its Universal Linkage System array reagent kits.

Through the deal, Kreatech gains global distribution rights for Repli-g for use with ULS for microarray applications in the life science research market. It will also develop and manufacture microarray amplification and labeling kits for genomic DNA and for array comparative genomic hybridization applications.

"Customers looking for amplification of small input volumes of genomic DNA for microarray applications will now be able to amplify and label directly for array CGH analysis," Brent Keller, Kreatech's general manager and vice president of commercial operations, said in a statement this week.

"I don't think they have changed their strategy of going after the microarray market or the array CGH market. They are going to allow us to do that for them."

"This will be the first amplification and labeling kit available for arrayCGH analysis that enables customers to detect genetic aberrations without introducing bias during the amplification and labeling, unlike conventional amplification and enzymatic labeling procedures," he added.

The deal also underscores Qiagen's 3-year-old strategy to leave the microarray reagent kit market for other players to compete in as it continues to invest in diagnostics and RT-PCR, according to a company official.

For example, Qiagen two weeks ago agreed to supply CytoPathfinder, a Japanese startup developing microarrays and drug-delivery technologies, with siRNAs for use on its transfection microarray for high-throughput RNAi screening (see RNAi News 6/1/2006).

Andreas Schäfer, the director R&D at Qiagen, said that the Kreatech alliance "is part of [Qiagen's] strategy to offer [its] products and technologies to partners in the microarray industry," rather than to market the kits to the array market itself.

Schäfer told BioArray News last week that Qiagen is instead "focused on … different markets including life science research markets, molecular diagnostics and applied testing markets."

Still, Schäfer admitted that its products have found their niche in the array market, and have even become what he called "standard" products. For example, he said that "most" microarray researchers are using Qiagen's line of RNeasy kits to purify RNA purification step, as well as its PAXgene Blood RNA Kit for stabilizing blood and purifying RNA.

'Rapidly Growing Market'

Qiagen, which employs 1,500 people, is not interested in directly marketing its kits to array users, though Kreatech, which employs just 25 staffers, is attempting to do just that.

According to Kreatech's Keller, the Repli-g deal represents another avenue for his company to build its identity in the array comparative genomic hybridization sector, which he said is a "very active and rapidly growing area with several platforms now on the market besides the homebrews."

"The array CGH market is important to us in helping to establish our brand identity and name in the marketplace," Keller told BioArray News. The company launched its first kit for array CGH in June 2005 (see BAN 6/22/2005).

Several years ago, Qiagen mulled licensing Kreatech's ULS technology to sell kits directly into the microarray market and "there were kits being developed specifically for Qiagen," Keller said. However, a management change in 2003, which resulted in the promotion of then-chief financial officer Peer Schatz to CEO, prompted Qiagen to change its attitude towards the microarray market (see BAN 10/29/2003) and caused the company to seek partners who could sell its technology, Keller said.

He said the deal with Kreatech reflects a continuation of this strategy. "I don't think [Qiagen has] changed [its] strategy of going after the microarray market or the array CGH market," Keller said. "They are going to allow us to do that for them."

More OEM Deals Planned

Though Qiagen has for now ruled out developing platforms or kits directly for the microarray market, it is looking to build its presence in the space via original equipment manufacturer agreements for customized reagent kits, similar to the deals it has made with Affymetrix and, more recently, Osmetech (see BAN 11/30/2005).

Qiagen's Schäfer said that the company last year hired an OEM manager for life science, so "the organization is now in place to look actively for more partners and more OEM business."

"We do expect more deals like this in the future," Schäfer said. "Since not every microarray company in this market is capable of providing good preanalytical solutions, we at Qiagen would like to place our preanalytical solutions into complete product offerings from Affymetrix to Agilent to Roche whatever," Schäfer added.

— Justin Petrone ([email protected])

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.